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1. Introduction
The Amaryllidaceae alkaloids have attracted much attention
due to their rich bioactivities, such as anti-Alzheimer, antifungal, 
antibacterial, and antineoplastic activities.1 Among these alka-
loids, lycorine (1)1,2 and its deoxygenated derivatives lycoranes 
(2a and b)3 possess the characteristic pyrrolophenanthridine skel-
eton (Figure 1). We have previously reported the asymmetric 
total synthesis of (–)-lycorine (1) using a chiral ligand-controlled 
asymmetric conjugate addition cascade.4,5 As a continuation of 
this study to show the utility of this cascade reaction, here we 
report a short asymmetric total synthesis of (+)-"-lycorane 
(2b).6,7,8 
Our strategy starts from the asymmetric conjugate addition9,10 
of aryllithium 4 to nona-2,7-dienedioate 311,12 mediated by chiral 
ligand 5 (Scheme 1). The subsequent intramolecular Michael 
reaction of the resulting enolate 6 would afford trisubstituted 
cyclohexane 7a with three contiguous stereogenic centers.4 The 
nitrogen functionality could be introduced by Curtius rearrange-
ment, and the subsequent cyclization gives (+)-"-lycorane (2b). 
Figure 1. Structures of lycorine and lycoranes. 
Scheme 1. Synthetic strategy to (+)-"-lycorane. 
2. Results and discussion
First, the reaction of dienedioate 3 and phenyllithium was in-
vestigated as a model reaction. The reaction of PhLi (3 equiv) in 
the presence of 5 (4.2 equiv) was complete within 0.5 h to give 
trans,trans-cyclohexane tt-7b with 71% ee and trans,cis-
cyclohexane tc-7b with 3% ee in 50% and 9% yields, respective-
ly (Table 1, entry 1). The relative configuration of tt-7b was as-
signed based on the trans-diaxial coupling between the two pairs 
of the adjacent methine protons (J = 11.2 Hz each). The absolute 
configuration of tt-7b was determined by conversion to a known 
compound with established stereochemistry (see Supplementary 
Material).  
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The chiral diether ligand-controlled asymmetric conjugate addition of organolithiums to nona-
2,7-dienedioate and subsequent intramolecular conjugate addition of the enolate intermediate 
gave all-trans trisubstituted cyclohexanes with high ee and yields. Using this methodology, an 
efficient short asymmetric total synthesis of (+)-!-lycorane was accomplished in 33% overall 
yield through five steps from the dienedioate. 
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Table 1. Asymmetric conjugate addition cascade.a 
entry Ar 7 
tt-7 tc-7 
yield (%) ee (%) yield (%) ee (%) 
1 Ph 7b 50 71b 9 3b 
2 2-MeC6H4 7c 63 68 7 42 
3 2-i-PrC6H4 7d 72 67b 16 61 
4 1-naphthyl 7e 79 81b 4 39b 
5 O
O




7a 68 99 18 88 
a All reactions were carried out using ArLi (3 equiv) and 5 (4.2 equiv). b The 
ee was determined after derivatization (see Supplementary Material). 
Toward the synthesis of (+)-"-lycorane, benzodioxol-5-
yllithium was employed in the cascade reaction. The reaction 
proceeded with comparable enantioselectivity, and tt-7f with 
74% ee was obtained in 40% yield along with tc-7f with 72% ee 
in 10% yield (entry 5). Although tt-7c and 7d were obtained with 
the same level of enantioselectivity (67–68% ee) in the reactions
with 2-methyl- and 2-isopropylphenyllithiums (entries 2 and 3), 
the enantioselectivity was improved in the reaction with 1-
naphthyllithium to give tt-7e with 81% ee in 79% yield along 
with tc-7e with 39% ee in 4% yield (entry 4). Encouraged by this 
result, we utilized aryllithium 4, bearing a bulky TMS group at 
the ortho-position, in the reaction. To our delight, tt-7a, which
has all the carbon atoms and stereochemistry required for the 
total synthesis, was obtained in 68% yield with almost perfect 
enantioselectivity (99% ee; entry 6). Interestingly, the products 
were obtained in higher yields with the more bulky aryllithiums 
(entries 1 and 5 vs 2–4 and 6). This is explainable by decreased 
order of aggregation of the organolithium compounds in solution 
by the steric hindrance.13 Unfortunately, lowering the amount of 
the aryllithium, the enantiomeric excesses of tt-7a and tc-7a were 
decreased to 85% and 54% (2 equiv), or to 50% and 27% (1.2 
equiv), respectively, although the yield and the diastereoselectivi-
ty were unchanged. These results indicate that the lithium enolate 
that was generated by the conjugate addition cascade would form 
a ternary complex with the aryllithium and chiral ligand, which 
undergoes less enantioselective conjugate addition.14 Importantly,
chiral ligand 5 was quantitatively recovered without any loss of 
optical purity, and was reusable. 
The diastereoselectivity of the cascade reaction is explainable 
as shown in Scheme 2. The lithium enolate intermediate, which 
results from the conjugate addition of 4 to 3, would undergo the 
intramolecular Michael reaction preferentially via conformer A 
and lead to tt-7a, due to the absence of the 1,3-diaxial repulsion 
of the alkenoate moiety, which exists in conformer B. Therefore, 
the lower diastereoselectivity (4:1, Table 1, entry 6) than that in 
the previously reported reaction of 4 and 8 to give 9 (9:1)4 could 
be attributed to the decreased 1,3-diaxial repulsion in conformer 
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Scheme 2. Rationale for observed diastereoselectivity. 
The asymmetric total synthesis of (+)-"-lycorane (2b) was ac-
complished starting from tt-7a as shown in Scheme 3. Treatment 
of tt-7a with HCl for 0.5 h in refluxing ethanol gave protodesi-
lylated half ester 10 in 98% yield. Interestingly and usefully, the 
carboxylic acid at the C-2 position was not esterified, probably 
due to steric hindrance.15  Curtius rearrangement using diphe-
nylphosphoryl azide (DPPA)16 followed by Bischler–Napieralski-
type cyclization with polyphosphoric acid (PPA)17 converted 10 
into lactam 11 via an isocyanate intermediate in 70% yield. Fi-
nally, treatment of 11 with borane–dimethyl sulfide complex18 in 
refluxing THF induced three sequential transformations: reduc-
tion of the lactam, lactam formation between the resulting amine 
and the ester moiety, and reduction of the resulting lactam to 
directly give (+)-"-lycorane (2b) in 70% yield. 1H and 13C 
NMR,6c,d and the specific rotation6d were in good agreement with 
those reported. Notably, the asymmetric total synthesis was ac-
complished through only five steps from 3 in high overall yield 
(33%). 
Scheme 3. Asymmetric total synthesis of (+)-"-lycorane (2b) 
3. Conclusion
This study revealed that the bulky TMS group at the ortho-
position of aryllithium is effective to improve the enantioselectiv-
ity of the chiral ligand-mediated asymmetric conjugate addition 
cascade of nonadienedioate. Cyclohexanes bearing three contig-
uous substituents with trans,trans-configuration were obtained in 
high optical purity. It was suggested that the 1,3-diaxial interac-
tion would play an important role in determining the diastereose-
lectivity. This methodology enables the formation of two C–C 
bonds and three stereogenic centers in one pot to give syntheti-
cally useful chiral cyclohexane derivatives. The utility of this 
methodology was clearly demonstrated by the achievement of the 
shortest asymmetric total synthesis of (+)-"-lycorane. Important-
ly, the chiral ligand could be recycled, and the one-pot reactions 




All melting points are uncorrected. Silica gel was used for 
column chromatography. 1H and 13C NMR (500 and 125 MHz, 
respectively) were measured in CDCl3 unless otherwise men-
tioned. Chemical shifts and coupling constants are presented in 
ppm # relative to tetramethylsilane and Hz, respectively. The 
wavenumbers of maximum absorption peaks of IR spectroscopy 
are presented in cm–1. Chiral ligand 5 was prepared as previously 
described.19 
4.1.1. Di-tert-butyl (2E,7E)-nona-2,7-dienedioate (3): 20  To a 
stirred suspension of tert-butyl triphenylphosphoranylideneace-
tate (161 g, 0.43 mol) in toluene (0.26 L) was added a solution of 
glutaraldehyde (17.2 g, 0.17 mol) in toluene (80 mL) at rt. After 
21 h, the mixture was filtered, and the residue was washed with 
hexane. The combined filtrate and washings were concentrated 
and purified by column chromatography (hexane/EtOAc = 20/1) 
to give the title compound (53 g, 90%) as a colorless oil of bp 
135–140 °C/0.2 mmHg: Rf = 0.4 (hexane/EtOAc = 9/1). 1H 
NMR: 1.48 (18H, s), 1.62 (2H, quintet, J = 7.3), 2.20 (4H, ddt, J 
= 1.5, 7.0, 7.3), 5.75 (2H, dt, J = 15.6, 1.5), 6.83 (2H, dt, J = 15.6, 
7.0). 13C NMR: 26.4 (CH2), 28.1 (CH3), 31.2 (CH2), 80.1 (C), 
123.6 (CH), 146.8 (CH), 165.9 (C). IR (neat): 1710, 1650. EIMS 
m/z: 223 (M – t-BuO). Anal. Calcd for C17H28O4: C, 68.89; H, 
9.52. Found: C, 68.87; H, 9.57. 1H NMR and IR spectra were in 
agreement with those reported,20 while 13C NMR had slight dif-
ference; 26.4 (CH2) instead of reported 29.7 (CH2). 
4.2. Asymmetric Conjugate Addition Cascade (Table 1) 
4.2.1. General Procedure. (1S,2S,3S)- and (1R,2S,3S)-tert-
Butyl 2-tert-butoxycarbonyl-3-(4-trimethylsilylbenzo[1,3]di-
oxol-5-yl)cyclohexaneacetate (tt-7a and tc-7a) (Table 1, entry 
3): To a solution of 5 (10.2 g, 42 mmol) and 3,4-methylenedioxy-
2-trimethylsilylbromobenzene 21  (8.19 g, 30 mmol) in toluene 
(280 mL) was added a solution of t-BuLi (1.69 M; 16.6 mL, 28 
mmol) in pentane at –78 °C, and the resulting solution was stirred 
for 1 h at the same temperature. A solution of 3 (2.96 g, 10 
mmol) in toluene (20 mL) was added at –78 °C, and the mixture 
was stirred for 10 min at the same temperature. The reaction was 
quenched by the addition of saturated NH4Cl. The organic layer 
was separated, and the aqueous layer was extracted with Et2O. 
The combined organic layers were successively washed with 
saturated NaHCO3 and brine, dried over Na2SO4, and concentrat-
ed. Column chromatography (hexane/Et2O = 30/1) gave tt-7a 
(3.31 g, 68%) with 99% ee and tc-7a (860 mg, 18%) with 88% ee 
as colorless oils, and 5 (10.2 g, quantitative recovery) as a color-
less solid. 
tt-7a: Rf = 0.4 (hexane/Et2O = 9/1, developed twice). [$]D25 
+16.8 (c 1.26, CHCl3). 1H NMR: 0.35 (9H, s), 1.07 (9H, s), 1.07–
1.20 (1H, m), 1.20–1.34 (2H, m), 1.42 (9H, s), 1.72–1.82 (2H, m), 
1.89 (1H, m), 2.01 (1H, dd, J = 9.8, 14.4), 2.05 (1H, m), 2.27 (1H, 
dd, J = 2.4, 14.4), 2.33 (1H, t, J = 11.0), 2.97 (1H, dt, J = 1.8, 
11.0), 5.78 (2H, m), 6.68–6.76 (2H, m). 13C NMR: 1.5 (CH3), 
25.5 (CH2), 27.6 (CH3), 28.0 (CH3), 30.6 (CH2), 36.1 (CH2), 37.6 
(CH), 40.2 (CH2), 45.4 (CH), 55.4 (CH), 79.6 (C), 80.1 (C), 99.4 
(CH2), 108.5 (CH), 119.0 (C), 120.1 (CH), 142.5 (C), 144.0 (C), 
152.2 (C), 171.4 (C), 173.3 (C). IR (neat): 1728. EIMS m/z: 490 
(M+). Anal. Calcd for C27H42O6Si: C, 66.09; H, 8.63. Found: C, 
65.92; H, 8.70. The ee was determined by HPLC (Daicel Chiral-
cel OD-H, hexane/i-PrOH = 1000/1, 1 mL/min, 250 nm; major 
9.5 min, minor 7.5 min). 
tc-7a: Rf = 0.5 (hexane/Et2O = 9/1, developed twice). [$]D25 
+11.7 (c 1.32, CHCl3). 1H NMR: 0.41 (9H, s), 1.18 (9H, s), 1.1–
1.3 (2H. m), 1.44 (9H, s), 1.52–1.62 (2H, m), 1.72–1.84 (2H, m), 
2.38 (1H, dd, J = 4.6, 15.2), 2.53 (1H, dd, J = 3.7, 15.2), 2.71 
(1H, m), 2.84 (1H, dd, J = 4.0, 11.8), 3.00 (1H, dt, J = 3.1, 11.8), 
5.83 (2H, m), 6.66 (1H, d, J = 8.2), 6.71 (1H, d, J = 8.2). 13C 
NMR: 1.6 (CH3), 20.5 (CH2), 27.8 (CH3), 28.1 (CH3), 29.4 (CH2), 
33.3 (CH), 34.2 (CH2), 37.0 (CH2), 38.5 (CH), 53.0 (CH), 79.7 
(C), 80.0 (C), 99.6 (CH2), 108.6 (CH), 118.0 (CH), 118.9 (C), 
143.9 (C), 144.4 (C), 152.5 (C), 172.4 (C), 172.6 (C). IR (neat): 
1728. EIMS m/z: 490 (M+). Anal. Calcd for C27H42O6Si: C, 66.09; 
H, 8.63. Found: C, 66.17; H, 8.70. The ee was determined by 
HPLC (Daicel Chiralcel OD-H, hexane/i-PrOH = 1000/1, 1 
mL/min, 250 nm; major 8.9 min, minor 7.5 min). 
4.2.2. tert-Butyl (1S,2S,3S)-2-(tert-butoxycarbonyl)-3-phenyl-
cyclohexaneacetate (tt-7b) (Table 1, entry 1): Rf = 0.5 (hexane/ 
EtOAc = 9/1). A white solid of mp 70–72 °C. 71% ee. [$]D25 
+14.0 (c 5.00, CHCl3). 1H NMR (C6D6): 1.12 (9H, s), 1.22–1.38 
(3H, m), 1.41 (9H, s), 1.60 (1H, m), 1.70 (1H, m), 2.02 (1H, m), 
2.24 (1H, dd, J = 9.5, 15.0), 2.34 (1H, t, J = 11.2), 2.40 (1H, m), 
2.60 (1H, dd, J = 3.1, 15.0), 2.81 (1H, dt, J = 3.4, 11.2), 7.05–
7.20 (5H, m). 13C NMR (C6D6): 26.0 (CH2), 27.2 (CH3), 28.1 
(CH3), 31.2 (CH2), 34.4 (CH2), 37.9 (CH), 40.7 (CH2), 48.3 (CH), 
56.1 (CH), 79.5 (C), 79.8 (C), 126.6 (CH), 128.3 (CH), 128.3 
(CH), 144.6 (C), 171.2 (C), 173.1 (C). IR (CHCl3): 1710. EIMS 
m/z: 374 (M+), 318, 262. Anal. Calcd for C23H34O4: C, 73.76; H, 
9.15. Found: C, 73.75; H, 9.33. The ee was determined after re-
duction with LiAlH4. The absolute configuration was determined 
after conversion into a known compound (see Supplementary 
Material). 
4.2.3. tert-Butyl (1R,2S,3S)-2-(tert-butoxycarbonyl)-3-phenyl-
cyclohexaneacetate (tc-7b) (Table 1, entry 1): Rf = 0.6 (hexane/ 
EtOAc = 9/1). A white solid of mp 90–95 °C. 3% ee. [$]D25 –19.8 
(c 2.04, CHCl3). 1H NMR: 1.15 (9H, s), 1.34–1.40 (1H, m), 1.45 
(9H, s), 1.58–1.62 (3H, m), 1.79 (1H, m), 1.87 (1H, m), 2.45 (1H, 
dd, J = 9.8, 15.6), 2.50 (1H, dd, J = 4.9, 15.6), 2.73 (1H, m), 2.82 
(2H, m), 7.15–7.25 (5H, m). 13C NMR: 20.6 (CH2), 27.7 (CH3), 
28.1 (CH3), 29.5 (CH2), 32.8 (CH), 34.2 (CH2), 35.0 (CH2), 40.9 
(CH), 52.6 (CH), 80.1 (C), 80.2 (C), 126.1 (CH), 127.4 (CH), 
128.1 (CH), 145.2 (C), 172.4 (C), 172.9 (C). IR (CHCl3): 1710. 
EIMS m/z: 374 (M+), 318, 262. Anal. Calcd for C23H34O4: C, 
73.76; H, 9.15. Found: C, 73.89; H, 9.00. The ee was determined 
after conversion to the corresponding dimethyl ester (see Sup-
plementary Material). 
4.2.4. (1S,2S,3S)-tert-Butyl 2-(tert-butoxycarbonyl)-3-(2-meth-
ylphenyl)cyclohexanacetate (tt-7c) (Table 1, entry 2): Rf = 0.5 
(hexane/Et2O = 9/1, developed twice). A colorless oil. 68% ee 
(HPLC: Daicel Chiralcel OD-H % 2 were connected, hexane/i-
PrOH = 100/1, 1 mL/min, 254 nm; major 37.5 min, minor 33.2 
min). [$]D25 +13.4 (c 2.16, CHCl3). 1H NMR: 1.07 (9H, s), 1.17 
(1H, m), 1.33 (1H, m), 1.46 (9H, s), 1.56 (1H, m), 1.81 (2H, m), 
1.94 (1H, m), 2.05 (1H, dd, J = 10.1, 14.7), 2.15 (1H, m), 2.32 
(1H, dd, J = 3.4, 14.7), 2.32 (3H, s), 2.36 (1H, t, J = 10.7), 3.06 
(1H, dt, J = 3.4, 11.9), 7.04–7.22 (4H, m). 13C NMR: 19.6 (CH3), 
25.9 (CH2), 27.5 (CH3), 28.1 (CH3), 31.0 (CH2), 33.7 (CH2), 37.5 
(CH), 40.5 (CH2), 42.1 (CH), 55.5 (CH), 79.9 (C), 80.2 (C), 
125.8 (CH), 125.9 (CH), 126.4 (CH), 130.0 (CH), 135.5 (C), 
142.1 (C), 171.7 (C), 173.6 (C). IR (neat): 1720. EIMS m/z: 388 
(M+), 332, 276. Anal. Calcd for C24H36O4: C, 74.19; H, 9.34. 
Found: C, 73.91; H, 9.47. 
4.2.5. (1R,2S,3S)-tert-Butyl 2-(tert-butoxycarbonyl)-3-(2-meth-
ylphenyl)cyclohexanacetate (tc-7c) (Table 1, entry 2): Rf = 0.6 
(hexane/Et2O = 9/1, developed twice). A colorless solid of mp 
60–75 °C. 42% ee (HPLC: Daicel Chiralcel OG, hexane/i-PrOH 
= 500/1, 0.5 mL/min, 254 nm; major 10.8 min, minor 15.8 min). 
[$]D25 –8.28 (c 0.79, CHCl3). 1H NMR: 1.12 (9H, s), 1.19–1.27 
(2H, m), 1.46 (9H, s), 1.59–1.63 (2H, m), 1.79–1.81 (2H, m), 
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2.36 (3H, s), 2.47 (1H, dd, J = 4.9, 15.3), 2.52 (1H, dd, J = 3.4, 
14.7), 2.76 (1H, m), 2.92 (1H, dd, J = 4.0, 12.2), 3.05 (1H, dt, J = 
3.7, 12.2), 7.02–7.15 (4H, m). 13C NMR: 19.6 (CH3), 20.8 (CH2), 
27.6 (CH3), 28.1 (CH3), 29.5 (CH2), 33.1 (CH), 34.0 (CH2), 34.1 
(CH2), 35.3 (CH), 52.5 (CH), 80.0 (C), 80.2 (C), 124.8 (CH), 
125.6 (CH), 126.0 (CH), 130.1 (CH), 135.6 (C), 143.5 (C), 172.4 
(C), 172.9 (C). IR (Nujol): 1730, 1710. EIMS m/z: 388 (M+), 332, 
276. Anal. Calcd for C24H36O4: C, 74.19; H, 9.34. Found: C, 
73.96; H, 9.38. 
4.2.6. (1S,2S,3S)-tert-Butyl 2-(tert-butoxycarbonyl)-3-(2-iso-
propylphenyl)cyclohexanacetate (tt-7d) (Table 1, entry 3): Rf 
= 0.4 (hexane/EtOAc = 9/1). A colorless oil. 67% ee. [$]D25 
+17.9 (c 5.11, CHCl3). 1H NMR: 1.05 (9H, s), 1.17 (3H, d, J = 
6.7), 1.25 (3H, d, J = 6.7), 1.27–1.52 (3H, m), 1.46 (9H, s), 1.82 
(1H, m), 1.95 (1H, m), 2.05 (1H, dd, J = 9.8, 14.7), 2.16 (1H, m), 
2.31 (1H, dd, J = 3.1, 14.7), 2.41 (1H, t, J = 11.0), 3.17 (1H, dt, J 
= 3.1, 11.0), 3.29 (1H, septet, J = 6.7), 7.10–7.26 (4H, m). 13C 
NMR: 23.2 (CH3), 24.6 (CH3), 26.0 (CH2), 27.5 (CH3), 28.12 
(CH), 28.14 (CH3), 30.9 (CH2), 35.0 (CH2), 37.7 (CH), 40.5 
(CH2), 41.3 (CH), 55.5 (CH), 79.9 (C), 80.2 (C), 124.8 (CH), 
125.3 (CH), 126.2 (CH), 126.9 (CH), 140.7 (C), 146.0 (C), 171.6 
(C), 173.7 (C). IR (neat): 1720. EIMS m/z: 416 (M+), 360, 304. 
Anal. Calcd for C26H40O4: C, 74.96; H, 9.68. Found: C, 75.17; H, 
9.83. The ee was determined after reduction with LiAlH4 (see 
Supplementary Material). 
4.2.7. (1R,2S,3S)-tert-Butyl 2-(tert-butoxycarbonyl)-3-(2-iso-
propylphenyl)cyclohexanacetate (tc-7d) (Table 1, entry 3): Rf 
= 0.5 (hexane/EtOAc = 9/1). A colorless solid of mp 79–81 °C. 
61% ee (HPLC: Daicel Chiralcel AD, hexane/i-PrOH = 100/1, 
0.5 mL/min, 254 nm; major 9.3 min, minor 8.2 min). [$]D25 –15.1 
(c 0.56, CHCl3). 1H NMR: 1.13 (9H, s), 1.20 (3H, d, J = 6.7), 
1.29 (3H, d, J = 6.7), 1.46 (9H, s), 1.59–1.67 (4H, m), 1.79–1.82 
(2H, m), 2.52 (1H, dd, J = 10.4, 15.6), 2.57 (1H, dd, J = 4.3, 
15.6), 2.76 (1H, m), 2.92 (1H, dd, J = 4.3, 11.9), 3.17 (1H, dt, J = 
3.4, 11.9), 3.32 (1H, septet, J = 6.7), 7.08–7.25 (4H, m). 13C 
NMR: 20.7 (CH2), 23.6 (CH3), 24.3 (CH3), 27.7 (CH3), 28.0 (CH), 
28.1 (CH3), 29.5 (CH2), 33.0 (CH), 33.9 (CH2), 34.5 (CH), 35.4 
(CH2), 52.5 (CH), 79.8 (C), 80.1 (C), 125.0 (CH), 125.2 (CH), 
125.4 (CH), 126.0 (CH), 141.7 (C), 146.1 (C), 172.5 (C), 172.8 
(C). IR (Nujol): 1710. EIMS m/z: 416 (M+), 360, 304. Anal. 
Calcd for C26H40O4: C, 74.96; H, 9.68. Found: C, 74.69; H, 9.66. 
4.2.8. (1S,2S,3S)- and (1R,2S,3S)-tert-Butyl 2-(tert-butoxycar-
bonyl)-3-(naphthalen-1-yl)cyclohexanacetate (tt-7e and tc-7e) 
(Table 1, entry 4): Rf = 0.6 (hexane/EtOAc = 9/1, developed 
twice). A colorless oil. A 79:4 mixture of tt-7e with 81% ee and 
tc-7e with 39% ee. [$]D25 –16.3 (c 5.00, CHCl3). 1H NMR: 0.88 
(9H, s), 0.98 (1.8H, s), 1.21–1.50 (3H, m), 1.21–2.10 (1.4H, m), 
1.48 (9H, s), 1.59 (1.8H, s), 1.66 (1H, m), 1.89 (1H, m), 2.01 (1H, 
m), 2.12 (1H, dd, J = 10.0, 15.0), 2.27 (1H, m), 2.38 (1H, dd, J = 
3.4, 15.0), 2.51 (0.2H, dd, J = 4.0, 15.3), 2.55 (1H, t, J = 11.0), 
2.65 (0.2H, dd, J = 11.0, 15.3), 2.86 (0.2H, m), 3.14 (0.2H, dd, J 
= 4.3, 11.9), 3.74 (1H, dt, J = 3.4, 11.0), 7.41–7.51 (4H, m), 
7.30–7.50 (1H, m), 7.67 (0.2H, d, J = 7.9), 7.68 (1H, d, J = 7.9), 
7.81 (1H, d, J = 8.1), 7.82 (0.2H, d, J = 8.0), 8.16 (1H, d, J = 8.6). 
13C NMR: (tt-7e) 26.0 (CH2), 27.3 (CH3), 28.1 (CH3), 31.2 (CH2), 
34.5 (CH2), 37.9 (CH), 40.5 (CH2), 40.9 (CH), 56.0 (CH), 80.0 
(C), 80.2 (C), 123.1 (CH), 123.7 (CH), 125.2 (CH), 125.3 (CH), 
125.7 (CH), 126.6 (CH), 128.6 (CH), 131.5 (C), 133.8 (C), 140.4 
(C), 171.7 (C), 173.1 (C); (tc-7e) 20.9 (CH2), 27.5 (CH3), 29.5 
(CH2), 33.4 (CH), 34.3 (CH2), 34.9 (CH2), 52.5 (CH), 80.1 (C), 
123.0 (CH), 125.3 (CH), 126.4 (CH), 128.8 (CH), 131.6 (C), 
133.8 (C), 141.8 (C), 172.3 (C), 172.8 (C). IR (neat): 1720. EIMS 
m/z: 424 (M+), 368, 312. Anal. Calcd for C27H36O4: C, 76.38; H, 
8.55. Found: C, 76.61; H, 8.64. The ee was determined after re-
duction with LiAlH4 (see Supplementary Material). 
4.2.9. (1S,2S,3S)-tert-Butyl 2-tert-butoxycarbonyl-3-(benzo[1, 
3]dioxol-5-yl)cyclohexaneacetate (tt-7f) (Table 1, entry 5): Rf = 
0.5 (hexane/Et2O = 4/1). A colorless oil. 74% ee (HPLC: Daicel 
Chiralcel OD-H, hexane/i-PrOH = 100/1, 1 mL/min, 250 nm; 
major 6.3 min, minor 7.0 min). [$]D25 +15.2 (c 1.24, CHCl3). 1H 
NMR: 1.10 (9H, s), 1.0–1.4 (3H, m), 1.38 (9H, s), 1.70–1.78 (2H, 
m), 1.84 (1H, m), 1.95 (1H, dd, J = 9.8, 14.6), 2.03 (1H, m), 2.11 
(1H, t, J = 11.0), 2.22 (1H, dd, J = 2.7, 14.6), 2.60 (1H, dt, J = 
2.4, 11.0), 5.81 (2H, m), 6.55 (1H, m), 6.60–6.63 (2H, m). 13C 
NMR: 25.5 (CH2), 27.6 (CH3), 28.0 (CH3), 30.7 (CH2), 34.1 
(CH2), 37.3 (CH), 40.3 (CH2), 47.3 (CH), 56.3 (CH), 79.8 (C), 
80.0 (C), 100.5 (CH2), 107.7 (CH), 107.9 (CH), 120.7 (CH), 
137.9 (C), 145.8 (C), 147.2 (C), 171.4 (C), 173.1 (C). IR (neat): 
1728. EIMS m/z: 418 (M+). Anal. Calcd for C24H34O6: C, 68.87; 
H, 8.19. Found: C, 69.01; H, 8.40. 
4.2.10. (1R,2S,3S)-tert-Butyl 2-tert-butoxycarbonyl-3-(benzo[1, 
3]dioxol-5-yl)cyclohexaneacetate (tc-7f) (Table 1, entry 5): Rf 
= 0.6 (hexane/Et2O = 4/1). A colorless oil. 72% ee (HPLC: 
Daicel Chiralcel OD-H, hexane/i-PrOH = 100/1, 1 mL/min, 250 
nm; major 6.2 min, minor 7.1 min). [$]D25 –20.1 (c 1.78, CHCl3). 
1H NMR: 1.21 (9H, s), 1.2–1.4 (2H, m), 1.44 (9H, s), 1.5–1.7 (2H, 
m), 1.76 (1H, m), 1.84 (1H, m), 2.42 (1H, dd, J= 9.5, 15.6), 2.48 
(1H, dd, J = 4.3, 15.6), 2.68–2.78 (3H, m), 5.89 (2H, m), 6.64 
(1H, m), 6.69–6.71 (2H, m). 13C NMR: 20.5 (CH2), 27.8 (CH3), 
28.1 (CH3), 29.5 (CH2), 32.8 (CH), 34.2 (CH2), 35.2 (CH2), 40.5 
(CH), 52.8 (CH), 80.10 (C), 80.12 (C), 100.7 (CH2), 107.8 (CH), 
107.9 (CH), 120.2 (CH), 139.3 (C), 145.6 (C), 147.3 (C), 172.4 
(C), 172.7 (C). IR (neat): 1728. EIMS m/z: 418 (M+). Anal. Calcd 
for C24H34O6: C, 68.87; H, 8.19. Found: C, 68.66; H, 8.22. 
4.3. Asymmetric total synthesis of (+)-"-lycorane (Scheme 3) 
4.3.1. (1S,2S,6S)-2-(Benzo[1,3]dioxol-5-yl)-6-ethoxycarbonyl-
methylcyclohexanecarboxylic acid (10): To a solution of tt-7a 
(2.94 g, 6.0 mmol) in EtOH (2 mL) was added anhydrous 35% 
HCl in EtOH (20 mL) at rt, and the mixture was heated under 
reflux for 0.5 h. Water was added at 0 °C, and the whole was 
extracted with Et2O. The organic layer was washed with brine, 
dried over Na2SO4, and concentrated. Column chromatography 
(hexane/EtOAc = 4/1) gave the title compound (2.03 g, 98%) as 
colorless needles of mp 90–91 °C: Rf = 0.4 (hexane/EtOAc = 4/1). 
[$]D25 +39.6 (c 1.00, CHCl3). 1H NMR: 1.11 (1H, m), 1.23 (3H, t, 
J = 7.0), 1.36–1.51 (2H, m), 1.82–1.90 (3H, m), 2.11–2.19 (2H, 
m), 2.26 (1H, t, J = 11.0), 2.36 (1H, m), 2.71 (1H, dt, J = 2.8, 
11.0), 4.09 (2H, q, J = 7.0), 5.89 (2H, s), 6.59 (1H, dd, J = 1.5, 
7.9), 6.64–6.68 (2H, m). 13C NMR: 14.1 (CH3), 25.4 (CH2), 30.9 
(CH2), 33.7 (CH2), 37.0 (CH), 39.4 (CH2), 46.6 (CH), 55.7 (CH), 
60.4 (CH2), 100.7 (CH2), 107.4 (CH), 108.0 (CH), 120.4 (CH), 
137.4 (C), 146.1 (C), 147.5 (C), 172.1 (C), 179.6 (C). IR (Nujol): 
2800–3300, 1720, 1685. EIMS m/z: 334 (M+), 288, 201, 135. 
Anal. Calcd for C18H22O6: C, 64.66; H, 6.63. Found: C, 64.61; H, 
6.55. 
4.3.2. (4S,4aR,11bR)-Ethyl (6-oxo-1,2,3,4,4a,5,6,11b-octahy-
dro[1,3]dioxolo[4,5-j]phenanthridin-4-yl)acetate (11): To a 
solution of 10 (1.84 g, 5.5 mmol) in toluene (16 mL) were added 
diphenylphosphoryl azide (1.3 mL, 6 mmol) and Et3N (0.92 mL, 
6.6 mmol) at 0 °C. The whole was heated under reflux for 0.5 h. 
After cooled to rt, the mixture was concentrated in vacuo to give 
colorless oil, which indicated the absorbance at 2250 cm–1 in the 
IR spectrum. To the above oil was added PPA (10 mL) at 0 °C, 
and the whole was stirred for 0.5 h at rt. Water was added, and 
the mixture was extracted with CHCl3. The organic layer was 
successively washed with water, saturated NaHCO3, and brine, 
5 
dried over Na2SO4, and concentrated. Column chromatography 
(CHCl3/EtOAc = 4/1), followed by recrystallization from EtOH 
gave the title compound (1.28 g, 70%) as colorless needles of mp 
205–206 °C: Rf = 0.3 (CHCl3/EtOAc = 4/1). [$]D25 +72.7 (c 1.06, 
CHCl3). 1H NMR: 1.17–1.36 (2H, m), 1.29 (3H, t, J = 7.0), 1.52 
(1H, m), 1.90–1.94 (2H, m), 2.05 (1H, m), 2.27 (1H, dd, J = 7.0, 
15.9), 2.34 (1H, m), 2.60 (1H, dd, J = 5.0, 15.9), 2.71 (1H, dt, J = 
3.7, 11.6), 3.03 (1H, t, J = 11.6), 4.19 (2H, q, J = 7.0), 6.00 (2H, 
m), 6.73 (1H, brs), 6.76 (1H, s), 7.51 (1H, s). 13C NMR: 14.1 
(CH3), 24.5 (CH2), 26.9 (CH2), 31.3 (CH2), 37.7 (CH), 37.8 (CH2), 
41.6 (CH), 59.6 (CH), 60.7 (CH2), 101.4 (CH2), 103.9 (CH), 
107.9 (CH), 123.2 (C), 138.0 (C), 146.4 (C), 151.0 (C), 165.8 (C), 
172.6 (C). IR (Nujol): 3200, 1735, 1660. EIMS m/z: 331 (M+), 
243, 216, 202. Anal. Calcd for C18H21NO5: C, 65.24; H, 6.39; N, 
4.23. Found: C, 65.02; H, 6.34; N, 4.25. 
4.3.3. (+)-"-Lycorane (2b): To a solution of 11 (662 mg, 2.0 
mmol) in THF (100 mL) was added BH3&SMe2 (10 M; 1.0 mL, 10 
mmol) at 0 °C, and the mixture was heated under reflux for 3 d. 
To the mixture was added 10% NaOH at 0 °C, and the whole was 
extracted with toluene. The organic layer was washed with brine, 
dried over Na2SO4, and concentrated. Column chromatography 
(EtOAc/EtOH = 4/1) gave the title compound (442 mg, 70%) as 
colorless plates of mp 72–73 °C (lit.3,22 mp 72–73 °C): Rf = 0.4 
(EtOAc/EtOH = 4/1). [$]D20 +153 (c 1.02, EtOH); lit. [$]D20 –
143.3 (c 1.04, EtOH) for the enantiomer,3 [$]D20 +142.5 (c 0.17, 
EtOH).22 1H NMR: 1.1–1.2 (2H, m), 1.35–1.55 (2H, m), 1.51 (1H, 
t, J = 10.5), 1.65 (1H, m), 1.9–2.05 (3H, m), 2.26–2.35 (2H, m), 
2.50 (1H, t, J = 10.5), 3.33 (1H, d, J = 14.3), 3.38 (1H, dt, J = 5.5, 
9.0), 4.06 (1H, d, J = 14.3), 5.87 (1H, brs), 5.88 (1H, brs), 6.50 
(1H, s), 6.71 (1H, s). 13C NMR: 26.4 (CH2), 28.2 (CH2), 28.8 
(CH2), 30.0 (CH2), 41.7 (CH), 42.9 (CH), 53.8 (CH2), 57.2 (CH2), 
71.8 (CH), 100.6 (CH2), 105.3 (CH), 106.8 (CH), 128.4 (C), 
131.2 (C), 145.6 (C), 146.1 (C). IR (CHCl3): 2928, 1593, 1485. 
EIMS m/z: 257 (M+). 1H NMR and 13C NMR are in good agree-
ment with those reported in ref 6c and 6b, respectively, while 
there are slight differences in 1H NMR and IR from those re-
ported in ref 6d, probably due to a misprint; ours 1.9–2.05 (3H, 
m) instead of reported 1.93–1.98 (2H, m) and 3.23 (1H, m), and
ours 1593 cm–1 instead of reported 1724 cm–1, respectively. 
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